Morgan Stanley raised the firm’s price target on Insulet (PODD) to $317 from $234 and keeps an Overweight rating on the shares. Insulet “had a strong 3Q print,” says the analyst, who cites “high quality growth, strong cash flow characteristics, and catalysts on the horizon” for the firm’s higher target following the company’s quarterly report.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio